This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MARCKS / Myristoylated alanine-rich C-kinase substrate · Western blot design guide
Design a Western Blot for MARCKS
Real validated MARCKS Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-MARCKS WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
MARCKS Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~31.6 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Appendix (total-target IHC; phospho state unverified) +4 more | |
| Negative control | Adipose tissue (total-target IHC; phospho state unverified) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Acetylated | |
| Caveat | Activation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated MARCKS Western Blot Protocols
The A04133S163 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | MCF-7 treated with PMA, sp2/0 treated with PMA, PC12 treated with PMA (catalog A04133S163) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% BSA in TBST (standard starting point) |
| Primary antibody | A04133S163; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected MARCKS Western Blot Band Size?
MARCKS is predicted at 31.6 kDa; no empirical band size is supplied, and any migration effect from its listed modifications remains unproven.
| Band near 31.6 kDa | Compatible with the predicted MARCKS mass; band identity needs confirmation |
| Band above 31.6 kDa | Could reflect altered migration of phosphorylated MARCKS; no shift is established |
| Weak or absent p-S163 band | The recognized phosphorylated state may be scarce |
| Band enriched in a membrane fraction | Consistent with MARCKS membrane localization |
💡Expected MARCKS appearanceMARCKS has a predicted mass of 31.6 kDa, but no empirical band size is supplied; the lead antibody recognizes p-S163, so confirm band identity and phosphorylation state with appropriate controls.
| UniProt predicted mass | 31.6 kDa is the sequence-based reference, not a measured band position |
| Phosphoserines 26 and 27 | Phosphorylation could affect migration; no apparent-size change is established |
| Phosphoserines 63 and 77 | Phosphorylation could affect migration; no apparent-size change is established |
| Myristate-associated lipid anchor | Its effect on apparent band size is not established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | The p-S163 state may be scarce, or membrane-associated MARCKS may be underrepresented | Check phosphorylation conditions and compare whole-cell and membrane-enriched samples |
| Band higher than expected | Phosphorylation could affect migration, but the cause is unconfirmed | Compare phosphatase-treated and untreated samples and verify MARCKS identity |
| Band lower than expected | No UniProt cleavage feature explains a smaller band | Check sample integrity and verify the band with an independent MARCKS antibody |
| Multiple bands | Different phosphorylation states are possible, but distinct bands are not established | Compare phosphatase-treated and untreated samples and verify each band's identity |
| Weak or no signal | The phospho-S163 antibody detects a state-specific epitope | Compare stimulated and unstimulated lysates with a total-MARCKS control |
Experiment evidence
Western blot images showing MARCKS band
A04133S163 · MARCKS
A04133-4 · MARCKS
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for MARCKS Western blot
🧪HPA-IHC candidate guidance (verify in WB): HPA tissue expression does not establish phosphorylation at the selected antibody epitope. Verify activation-state controls for the phospho-specific lead. HPA-IHC candidate guidance (verify in WB): For positive controls for MARCKS in Western blot, you can use appendix tissue, which shows high expression in HPA.
Positive control: Appendix (total-target IHC; phospho state unverified)
Negative control: Adipose tissue (total-target IHC; phospho state unverified)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: MARCKS can move between membrane and cytoplasm, so keep lysate preparation consistent.
HPA tissue expression evidence for MARCKS
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cerebellum | molecular layer - neuropil | High | Protein (IHC) | HPA → |
| Colon | glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | glandular cells | High | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Liver | cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MARCKS Western Blot Tips
Deeper troubleshooting and optimisation questions for MARCKS, answered from its protein features.
How should MARCKS band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could MARCKS isoforms explain multiple bands?
Isoforms · The supplied record lists one isoform and no alternative sequence. It therefore provides no isoform-based explanation for multiple bands. Check band identity before assigning additional bands to MARCKS.
Which MARCKS sites are phosphorylated by PKC?
PTM · The supplied UniProt features identify phosphoserines at positions 159, 163, 167, and 170 as phosphorylated by PKC. Use these UniProt coordinates when selecting or interpreting a phospho-specific antibody; antibody or paper numbering may use a different convention.
Measure the phospho-specific signal against total MARCKS from matched samples. If using fractions, compare corresponding fractions across conditions because PKC-dependent phosphorylation changes membrane association. Record the antibody's site numbering convention before interpreting results against the UniProt positions.
Measure the phospho-specific signal against total MARCKS from matched samples. If using fractions, compare corresponding fractions across conditions because PKC-dependent phosphorylation changes membrane association. Record the antibody's site numbering convention before interpreting results against the UniProt positions.
Does this guide establish induction of MARCKS?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for MARCKS?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A04133S163 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should MARCKS be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Should MARCKS migrate at its predicted 31.6 kDa?
Interpretation · Use 31.6 kDa as the calculated reference, not an expected band position. The supplied record gives no empirical apparent mass. Its phosphorylation and lipid anchor are relevant features, but their presence alone does not establish a visible shift or explain any difference from 31.6 kDa.
The location note states that PKC-dependent phosphorylation displaces MARCKS from the cell membrane and dephosphorylation accompanies reassociation. If comparing conditions, examine matched membrane and cytoplasmic fractions alongside total lysate; a fraction-specific change may reflect redistribution.
The record lists 22 modified residues, including phosphoserine, phosphothreonine, and N6-acetyllysine at UniProt position 172. These features suggest modifications to investigate, but do not establish that a particular extra band is MARCKS or that a modification causes its mobility. Verify band identity and compare relevant phospho-specific signals.
The location note states that PKC-dependent phosphorylation displaces MARCKS from the cell membrane and dephosphorylation accompanies reassociation. If comparing conditions, examine matched membrane and cytoplasmic fractions alongside total lysate; a fraction-specific change may reflect redistribution.
The record lists 22 modified residues, including phosphoserine, phosphothreonine, and N6-acetyllysine at UniProt position 172. These features suggest modifications to investigate, but do not establish that a particular extra band is MARCKS or that a modification causes its mobility. Verify band identity and compare relevant phospho-specific signals.
Boster reagents
MARCKS Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-MARCKS (phospho-S163) Antibody
Cat # A04133S163
Real WB data
Anti-MARCKS Antibody Picoband®
Cat # A04133-4
Two anti-MARCKS antibodies have WB images: a phospho-S163 antibody tested on PMA-treated MCF-7, sp2/0, and PC12 lysates, and a MARCKS antibody tested on human SH-SY5Y and U251 lysates. The latter shows an approximately 80 kDa band despite a stated 32 kDa expected size.
Which to pick: Choose A04133S163 for the S163-phosphorylated form or A04133-4 for MARCKS without a phosphorylation-specific requirement. Both list human, mouse, and rat reactivity, but their WB images show only the named lysates and conditions; assess the 80 versus 32 kDa discrepancy for A04133-4.
Source: BosterBio MARCKS gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P29966.
- Human Protein Atlas. MARCKS tissue expression.
- PMC4607481 — target-verified WB comparison
- PMC2677811 — target-verified WB comparison
- PMC3660367 — target-verified WB comparison